Topoisomerase Inhibitors - Pipeline Insight, 2022

“Topoisomerase Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 60+ companies and 70+ pipeline drugs in Topoisomerase Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Topoisomerase Inhibitors Understanding

Topoisomerase Inhibitors: Overview

The topoisomerase enzymes play an important role in DNA metabolism, and searching for enzyme Inhibitors is an important target in the search for new anticancer drugs. Discovery of new anticancer chemotherapeutical capable of inhibiting topoisomerase enzymes is highlighted in anticancer research. Therefore, biologists, organic chemists and medicinal chemists all around the world have been identifying, designing, synthesizing and evaluating a variety of novel bioactive molecules targeting topoisomerase. Development of new anti-topoisomerase drugs, e.g. may allow to limit the cardiotoxic effect of anthracyclines or reduce the incidence of drug-induced secondary cancers. After all, the growing importance and rapid development of molecular genetics and molecular biology may enable the use of anti-topoisomerase agents in personalised anticancer therapy.

""Topoisomerase Inhibitors - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Topoisomerase Inhibitors pipeline landscape is provided which includes the disease overview and Topoisomerase Inhibitors treatment guidelines. The assessment part of the report embraces, in depth Topoisomerase Inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Topoisomerase Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Topoisomerase Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Topoisomerase Inhibitors.

Topoisomerase Inhibitors Emerging Drugs Chapters

This segment of the Topoisomerase Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Topoisomerase Inhibitors Emerging Drugs
• Datopotamab deruxtecan - Daiichi Sankyo

Datopotamab deruxtecan is currently being evaluated in a comprehensive development program across lung cancer and other solid tumors including breast cancer. Daiichi Sankyo and AstraZeneca entered into a global collaboration to jointly develop and commercialize datopotamab deruxtecan in July 2020, except in Japan where Daiichi Sankyo maintains exclusive rights for each ADC. Daiichi Sankyo is responsible for manufacturing and supply of datopotamab deruxtecan. It is currently in Phase III stage of development for the treatment of Non-small cell lung cancer and acts as Inhibitors of DNA topoisomerase I.
• Aldoxorubicin: ImmunityBio

Aldoxorubicin is a rationally-engineered cytotoxic which delivers well-established anti-cancer agent, doxorubicin, into the tumor. Currently in late-stage clinical trials, aldoxorubicin appears to overcome the key limitations of doxorubicin, including cumulative dose restrictions. Aldoxorubicin utilizes an acid-sensitive linker that selectively binds to albumin, which may allow the cytotoxic payload to preferentially accumulate in the tumor and potentially spare the surrounding healthy tissue. This mechanism leverages the tumor's low pH environment, and accompanying dependency upon circulating albumin to fuel growth, to enable the delivery of multifold times the standard dosing of doxorubicin. In July 2017, CytRx out-licensed the worldwide rights to aldoxorubicin to NantCell, Inc. (now called ImmunityBio, Inc.). It is currently in Phase III stage of development and acts as Inhibitors of Type II DNA topoisomerase, Reactive oxygen species stimulants and DNA intercalators.

Further product details are provided in the report……..

Topoisomerase Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Topoisomerase Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Topoisomerase Inhibitors

There are approx. 60+ key companies which are developing the therapies for Topoisomerase Inhibitors. The companies which have their Topoisomerase Inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Daiichi Sankyo.
• Phases

DelveInsight’s report covers around 70+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Topoisomerase Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Topoisomerase Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Topoisomerase Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Topoisomerase Inhibitors drugs.

Topoisomerase Inhibitors Report Insights
• Topoisomerase Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Topoisomerase Inhibitors Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Topoisomerase Inhibitors drugs?
• How many Topoisomerase Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Topoisomerase Inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Topoisomerase Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Topoisomerase Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Daiichi Sankyo
• ImmunityBio
• Monopar Therapeutics
• Luye Pharma
• Avacta
• Tarveda Therapeutics
• Cebiotex
• Cybrexa

Key Products
• Datopotamab deruxtecan
• Aldoxorubicin
• Trastuzumab deruxtecan
• Camsirubicin
• LY 01610
• AVA6000
• PEN-866
• CEB-01
• CBX-12